BioCentury
ARTICLE | Clinical News

HCV data buoys BMS

October 16, 2012 1:33 AM UTC

Shares of Bristol-Myers Squibb Co. (NYSE:BMY) gained on Monday on the release of an abstract of Phase IIa HCV data slated for presentation at November's American Association for the Study of Liver Diseases meeting in Boston. An all oral regimen of three of the pharma's antivirals led to a sustained virologic response (SVR) four weeks after the end of treatment in 94% of patients who received the regimen for 12 weeks. SVR4 data for patients who received the regimen for 24 weeks are not yet available. All patients had HCV RNA levels less than 25 IU/mL by week 4 of treatment and there were no virologic breakthroughs or relapses. The trial enrolled treatment-naïve patients with HCV genotype 1 infection. Bristol-Myers rose $0.84 to $33.93 on Monday, adding $1.4 billion in market cap for a valuation of $57 billion. ...